Cancer Therapy : Preclinical Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p 53 , PI 3 K / AKT , and NFk B
暂无分享,去创建一个
C. Eckert | I. Fichtner | K. Seeger | J. Hof | J. Prada | S. Shalapour | M. Pfau | A. Stackelberg | L. Bastian | unter Henze